Company intelligence / Profile preview

Astion Pharma

Vissenbjerg, Syddanmark, Denmarkastionpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Astion Pharma has developed commercial products for eczema treatment. Historically, they had drug candidates including ASF-1096 for cutaneous lupus erythematosus which completed Phase I with favorable results and was advancing to Phase III, and ASF-1057 for seborrheic dermatitis which was in Phase II studies in France and the UK[3].

Therapeutic areas: ImmunologyDermatology
Modalities: Topical creamspharmaceutical products
Industry: Biotech

Drug pipeline

5 assets

ASF-1057

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Astion Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astion Pharma.

Explore the full profile